Jiangxi Wannianqing Pharmaceutical

Jiangxi Wannianqing Pharmaceutical is a publicly traded Chinese pharmaceutical company focused on the modernization of Traditional Chinese Medicine (TCM) and the production of chemical drugs. The company's portfolio spans several therapeutic areas, including hepatology, endocrinology, cardiovascular health, and respiratory medicine. Its flagship product, Compound Biejia Ruangan Tablets, is a widely recognized treatment for liver fibrosis and early-stage cirrhosis in China. Based in Nanchang, the company maintains large-scale GMP-certified manufacturing facilities and a robust distribution network. Jiangxi Wannianqing is committed to integrating traditional herbal knowledge with modern pharmacological standards to serve the domestic and international healthcare markets.